WO1994003186A1 - Gel mucoadhesif vaginal, medicament le contenant et procede de preparation dudit gel - Google Patents
Gel mucoadhesif vaginal, medicament le contenant et procede de preparation dudit gel Download PDFInfo
- Publication number
- WO1994003186A1 WO1994003186A1 PCT/FR1993/000769 FR9300769W WO9403186A1 WO 1994003186 A1 WO1994003186 A1 WO 1994003186A1 FR 9300769 W FR9300769 W FR 9300769W WO 9403186 A1 WO9403186 A1 WO 9403186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gel according
- aqueous gel
- vaginal
- prevent
- mucoadhesion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to an aqueous mucoadhesive gel for local use, in particular vaginal or even rectal or intestinal. It also relates to a medicament containing this gel and possibly one or more therapeutically active substances intended (s) in particular to prevent or to treat the symptoms related to the vaginal dryness, as well as infectious pathologies of the vagina and the prevention of post-menopausal vaginal atrophies or pathologies of the rectal or intestinal mucosa. Finally, it relates to a process for preparing said gel.
- Aqueous gels based on cellulose derivatives, most often (hydroxypropyl- and methyl-cellulose), whose adhesive properties are poor, their only real action being to ensure the lubrication of the mucous membranes. These gels should be applied daily as a minimum.
- Oil-in-water emulsions containing thickening agents are more effective than previous gels and applications can be renewed only every two or three days.
- a first object of the present invention is to provide a long-lasting mucoadhesive gel for the vaginal mucosa making it possible to deliver one or more active ingredients for several days.
- a second object of the present invention is to provide a vaginal mucoadhesive gel making it possible to respect the microbial ecology of the vaginal flora by a physiological mechanism.
- a third object of the present invention is to provide a gel making it possible to offer patients the facilities of a spaced periodic application, for example every three days, which corresponds to the cycle of renewal of the epithelial cells of the vaginal mucosa.
- a fourth object of the present invention is to provide a mucoadhesive gel which, by means of an appropriate delivery system, can be applied to the rectal or intestinal mucosa.
- the aqueous gel according to the present invention comprises a natural polysaccharide having film-forming and bioadhesive properties and a mucoadhesion promoting agent.
- the aqueous gel according to the invention consists in percentage by weight:
- the gel of the present invention preferably comprises a water content greater than 80%, advantageously greater than 85%.
- polysaccharides which can be used in the context of the present invention must have good film-forming, bioadhesive and lubricating qualities required for application to the mucous membranes. They must, of course, be completely harmless to the mucous membranes and in particular respect the existing microbial balance as well as possible.
- Natural polysaccharides are divided into three categories, namely: nonionic, anionic and cationic. These polysaccharides are described in particular in the article by Georges L. Brode, Cosmetic and
- anionic polysaccharides which are suitable in the context of the present invention, there may be mentioned carrageenans or alginates.
- cationic polysaccharides suitable in the context of the present invention mention may be made of guar type polysaccharides.
- the mucoadhesion promoters are defined according to the present invention, as products which increase the adhesion capacities of a polysaccharide placed in an aqueous medium, without significantly modifying the viscosity of the initial polysaccharide gel.
- mucoadhesion promoting agents which are suitable in the context of the present invention are chosen from:
- hydrating agents suitable for the present invention one will advantageously use one of the physiologically acceptable salts of pyroglutamic acid.
- NMF Natural Moisturiser Factor
- hydrating agents such as urea, glycerin may also be suitable.
- nonionic surfactants suitable for the present invention advantageously one of the fatty acid esters of physiologically acceptable polyoxyethylene is used.
- sodium taurocholate will advantageously be used.
- EDTA EDTA will advantageously be used.
- fatty acids oleic acid, capric and caprylic acids and their physiologically acceptable salts will advantageously be used.
- adheresion promoter should be understood to mean a means which, while not significantly modifying the viscosity of the gel, increases the capacity for mucoadhesion, preferably at least 20%. Generally between 20 and 80%.
- the mucoadhesion index can be measured by performing the following test: a metal plate of 1 cm2 covered with a gel and connected to a strain gauge is applied to a mucosa. After 1 min, the separation force is measured.
- the suitable adhesion promoter for example, in the case of a carrageenan gel, in addition to sodium pyroglutamate, mention may also be made of sodium taurocholate.
- a preferred gel contains carrageenans extracted in particular from
- Rhodophytes especially of the species Gigartina or preferably Chondrus. It can be a mixture of 55 to 75% of lambda type carrageenans and 45 to 25% of carrageenans in almost equal proportion of iota and kappa type.
- the gel according to the invention contains in percentage by weight:
- the gel contains in percentage by weight:
- the balance of the compositions is practically constituted by water optionally added with pH-regulating excipients, for example, such as lactic acid and / or active ingredients as described above.
- the natural polysaccharide, water and the mucoadhesion promoter are mixed intimately, until a gel is formed, in particular in the proportions and with the characteristics described. previously.
- the mixing of the various constituents can be carried out by a process known to those skilled in the art.
- the gel can be used for the actual treatment of vaginal dryness as a medicine alone or as a vector for other active ingredients.
- the drug is intended in particular to prevent and treat infectious vaginal pathologies and to prevent and treat post-menopausal vaginal atrophy.
- active principles mention may be made of povidone iodine, econazole nitrate, estradiol.
- the gel can also be used as an excipient for the application of active ingredients for vaginal topical use, such as: hormones (estrogens for example), antifungals, antiseptics, anti-inflammatories.
- active ingredients such as: hormones (estrogens for example), antifungals, antiseptics, anti-inflammatories.
- the gel may also be used as an excipient for the application of active principles for topical rectal or intestinal use.
- the subject of the invention is therefore a medicament containing, in addition to the gel according to the invention, optionally one or more active principles, said medicament being more particularly intended for the abovementioned applications.
- the active ingredient will generally be present at 0.001% to 10% by weight.
- the gel according to the present invention has the advantage of not requiring daily application. On the contrary, it offers the possibility of an application every three days for example, which corresponds to the cycle of renewal of the epithelial cells of the mucosa.
- the product has the following properties:
- the gel according to the present invention Compared with an oil-in-water emulsion type product containing glycerin and a thickening agent (polycarbophil), the gel according to the present invention has the following advantages:
- a higher lubricating power of 30% (Method: measurement of the displacement force of a mucosal plate system),.
- a highly hydrophilic, flexible, resistant film is formed in the case of the product according to the present invention; the emulsion mentioned above does not produce anything similar.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6505050A JPH08500578A (ja) | 1992-07-31 | 1993-07-27 | 粘膜付着性膣用ゲル、それを含む医薬品、およびゲルの製造方法 |
EP93917832A EP0606457A1 (fr) | 1992-07-31 | 1993-07-27 | Gel mucoadhesif vaginal, medicament le contenant et procede de preparation dudit gel |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR92/09557 | 1992-07-31 | ||
FR9209557A FR2694194B1 (fr) | 1992-07-31 | 1992-07-31 | Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994003186A1 true WO1994003186A1 (fr) | 1994-02-17 |
Family
ID=9432529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1993/000769 WO1994003186A1 (fr) | 1992-07-31 | 1993-07-27 | Gel mucoadhesif vaginal, medicament le contenant et procede de preparation dudit gel |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0606457A1 (fr) |
JP (1) | JPH08500578A (fr) |
CA (1) | CA2120345A1 (fr) |
FR (1) | FR2694194B1 (fr) |
WO (1) | WO1994003186A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997030693A1 (fr) * | 1996-02-26 | 1997-08-28 | Dong Wha Pharmaceutical Industrial Co., Ltd. | Composition de suppositoire renfermant un medicament a effet de premier passage hepatique |
WO1997034580A1 (fr) * | 1996-03-21 | 1997-09-25 | Dong Wha Pharmaceutical Industrial Co., Ltd. | Composition pour suppositoires d'un medicament provoquant, en cas d'administration orale, des troubles gastro-intestinaux ou se decomposant sous l'effet de l'acide gastrique |
US6488954B1 (en) | 1999-02-24 | 2002-12-03 | Dong Wha Pharm. Ind. Co., Ltd. | Liquid suppository composition of diclofenac sodium |
AT411327B (de) * | 2001-08-23 | 2003-12-29 | Heil Bettina | Hormonpräparat mit ungesättigten fettsäuren |
US7910132B2 (en) | 1998-09-24 | 2011-03-22 | Orexo Ab | Pharmaceutical composition for the treatment of acute disorders |
US10287261B2 (en) | 2015-05-13 | 2019-05-14 | H. Lundbeck A/S | Vortioxetine pyroglutamate |
US10562872B2 (en) | 2016-02-08 | 2020-02-18 | H. Lundbeck A/S | Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292102A1 (en) * | 2004-12-10 | 2006-12-28 | Roman Stephen B | Thixotropic personal lubricant |
FR2912656B1 (fr) * | 2007-02-15 | 2009-05-08 | Dermaconcept Jmc Sarl | Composition pharmaceutique de type emulsion huile dans huile |
JP7237207B2 (ja) * | 2019-06-14 | 2023-03-10 | ザ プロクター アンド ギャンブル カンパニー | 洗い流さない口腔ケア組成物 |
BR112021024266A2 (pt) | 2019-06-14 | 2022-01-11 | Procter & Gamble | Composições para tratamento bucal sem enxágue |
EP3982913A1 (fr) | 2019-06-14 | 2022-04-20 | The Procter & Gamble Company | Compositions de soins buccaux sans rinçage |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2085737A1 (fr) * | 1970-03-24 | 1971-12-31 | Itek Corp | |
EP0125759A2 (fr) * | 1983-03-17 | 1984-11-21 | Warner Lambert Holland B.V. | Composition topique à base d'antibiotiques pour le traitement des muqueuses |
EP0363224A1 (fr) * | 1988-10-07 | 1990-04-11 | Block Drug Company Inc. | Traitement de la parodontite |
EP0362668A1 (fr) * | 1988-10-06 | 1990-04-11 | Degussa Aktiengesellschaft | Dérivés de l'acide pyrrolidone-2 carboxylique-5 et procédé pour leur obtention |
EP0410696A1 (fr) * | 1989-07-28 | 1991-01-30 | E.R. Squibb & Sons, Inc. | Système dispenseur en forme hydrogel adhésive à la muqueuse |
-
1992
- 1992-07-31 FR FR9209557A patent/FR2694194B1/fr not_active Expired - Fee Related
-
1993
- 1993-07-27 EP EP93917832A patent/EP0606457A1/fr not_active Withdrawn
- 1993-07-27 JP JP6505050A patent/JPH08500578A/ja active Pending
- 1993-07-27 CA CA 2120345 patent/CA2120345A1/fr not_active Abandoned
- 1993-07-27 WO PCT/FR1993/000769 patent/WO1994003186A1/fr not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2085737A1 (fr) * | 1970-03-24 | 1971-12-31 | Itek Corp | |
EP0125759A2 (fr) * | 1983-03-17 | 1984-11-21 | Warner Lambert Holland B.V. | Composition topique à base d'antibiotiques pour le traitement des muqueuses |
EP0362668A1 (fr) * | 1988-10-06 | 1990-04-11 | Degussa Aktiengesellschaft | Dérivés de l'acide pyrrolidone-2 carboxylique-5 et procédé pour leur obtention |
EP0363224A1 (fr) * | 1988-10-07 | 1990-04-11 | Block Drug Company Inc. | Traitement de la parodontite |
EP0410696A1 (fr) * | 1989-07-28 | 1991-01-30 | E.R. Squibb & Sons, Inc. | Système dispenseur en forme hydrogel adhésive à la muqueuse |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997030693A1 (fr) * | 1996-02-26 | 1997-08-28 | Dong Wha Pharmaceutical Industrial Co., Ltd. | Composition de suppositoire renfermant un medicament a effet de premier passage hepatique |
WO1997034580A1 (fr) * | 1996-03-21 | 1997-09-25 | Dong Wha Pharmaceutical Industrial Co., Ltd. | Composition pour suppositoires d'un medicament provoquant, en cas d'administration orale, des troubles gastro-intestinaux ou se decomposant sous l'effet de l'acide gastrique |
US7910132B2 (en) | 1998-09-24 | 2011-03-22 | Orexo Ab | Pharmaceutical composition for the treatment of acute disorders |
US8454996B2 (en) | 1998-09-24 | 2013-06-04 | Orexo Ab | Pharmaceutical composition for the treatment of acute disorders |
US8512747B2 (en) | 1998-09-24 | 2013-08-20 | Orexo Ab | Pharmaceutical composition for the treatment of acute disorders |
US6488954B1 (en) | 1999-02-24 | 2002-12-03 | Dong Wha Pharm. Ind. Co., Ltd. | Liquid suppository composition of diclofenac sodium |
AT411327B (de) * | 2001-08-23 | 2003-12-29 | Heil Bettina | Hormonpräparat mit ungesättigten fettsäuren |
US10287261B2 (en) | 2015-05-13 | 2019-05-14 | H. Lundbeck A/S | Vortioxetine pyroglutamate |
US11279682B2 (en) | 2015-05-13 | 2022-03-22 | H. Lundbeck A/S | Vortioxetine pyroglutamate |
US10562872B2 (en) | 2016-02-08 | 2020-02-18 | H. Lundbeck A/S | Synthesis of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine |
Also Published As
Publication number | Publication date |
---|---|
FR2694194B1 (fr) | 1994-11-04 |
EP0606457A1 (fr) | 1994-07-20 |
FR2694194A1 (fr) | 1994-02-04 |
JPH08500578A (ja) | 1996-01-23 |
CA2120345A1 (fr) | 1994-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2762782A1 (fr) | Composition comprenant un milieu de culture de micro-organisme et utilisation | |
AU746019B2 (en) | Topical non-steroidal anti-inflammatory drug composition | |
WO1994003186A1 (fr) | Gel mucoadhesif vaginal, medicament le contenant et procede de preparation dudit gel | |
CA2266798C (fr) | Utilisation d'au moins un hydroxystilbene en tant qu'agent diminuant l'adhesion des micro-organismes | |
FR3064473A1 (fr) | Ingredient protecteur de l'equilibre de la flore microbienne cutanee et/ou mucosale | |
CA2446549C (fr) | Composition cosmetique a base de sucralfate et de sulfates de cuivre et de zinc | |
FR3112953A1 (fr) | Utilisation cosmétique du sacran | |
EP2954902B1 (fr) | Composition à base d'extrait de pépin de pamplemousse, d'extrait de feuille d'alchémille, d'extrait de stevia et de curcumine | |
EP1530480B1 (fr) | Composition cosmetique comprenant des mono- ou poly-saccharides, utilisations et procedes de traitement | |
EP0865290B1 (fr) | Compositions pharmaceutiques pour application buccale comprenant un nsaid et des ceramides | |
CA2248235C (fr) | Utilisation du miel en tant qu'agent diminuant l'adhesion des micro-organismes | |
EP2343038B1 (fr) | Compositions dermatologiques contenant une association de lipides peroxydés et de zinc et leurs utilisations notamment dans le traitement de l'herpès | |
WO2009010587A1 (fr) | Utilisation d'au moins un extrait de parties aériennes de l'epilobe et/ou de l'onagre pour la préparation d'une composition destinée à restaurer la fonction barrière des tissus kératinisés ou des muqueuses. | |
EP2376055B1 (fr) | Composition cosmétique comprenant un hydrolysat de gomme de caroube | |
FR2797584A1 (fr) | Utilisation de lipides peroxydes dans le traitement ou la prevention des plaies et inflammations des muqueuses de la cavite buccale | |
FR2765803A1 (fr) | Composition cosmetique ou dermopharmaceutique pour application topique | |
WO2023186353A1 (fr) | Dextrines hyperbranchees pour leur utilisation topique pour la prevention ou le traitement d'au moins un symptome de l'inflammation cutanee | |
WO1993022370A1 (fr) | Derives d'acide undecylenique avec des macromolecules hydrophiles et utilisations en cosmetique ou en pharmacie | |
FR3072877A1 (fr) | Utilisation cosmetique d’un melange d’oligo-carraghenanes pour prevenir ou traiter les signes du vieillissement de l’epiderme | |
JPH09208449A (ja) | 清涼感付与剤および人体用組成物 | |
WO2001093858A2 (fr) | Utilisation d'un complexe d'aluminium et de ligand ethylenediamine-tetraacetique pour la prevention et/ou le traitement des urticaires | |
FR3023166A1 (fr) | Utilisation d'une composition pharmaceutique renfermant une pectine a titre de principe actif, dans la prevention et/ou le traitement des lesions cutanees impliquant un caractere inflammatoire |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993917832 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2120345 Country of ref document: CA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1993917832 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1994 211296 Country of ref document: US Date of ref document: 19940727 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993917832 Country of ref document: EP |